Phreesia Stock Price, News & Analysis

Phreesia (NYSE:PHR) has priced its public offering of 4,500,000 shares at $50.00 each, aiming for net proceeds of approximately $213.2 million. An additional 675,000 shares can be purchased by underwriters. The offering is set to close on April 12, 2021, subject to customary conditions. The company intends to use the funds raised to enhance its patient intake management platform, which aims to improve efficiency in healthcare organizations. Financial representatives include J.P. Morgan and William Blair.

Phreesia, Inc. (NYSE: PHR) has initiated an underwritten public offering of 4,500,000 shares of its common stock. Additionally, underwriters may acquire up to 675,000 shares more within 30 days. This offering is subject to market conditions and the actual size may vary. J.P. Morgan and William Blair are the joint book-running managers, with Allen & Company LLC and Piper Sandler as passive book-running managers. The offering will be made via a prospectus supplement and is compliant with SEC regulations.

Phreesia, Inc. (NYSE: PHR) reported its financial results for the fiscal fourth quarter and year ending January 31, 2021. The company achieved a 27% year-over-year revenue increase to $41.8 million for Q4 and a 19% increase to $148.7 million for the fiscal year. However, adjusted EBITDA for Q4 turned negative at $0.09 million, down from $1.3 million the previous year, and cash reserves decreased by $35.3 million to $218.8 million. Looking ahead, Phreesia projects revenue growth between $178 million and $186 million for fiscal 2022, maintaining previous growth guidance.

Phreesia has partnered with New Jersey Urology (NJU) to enhance the patient intake process across over 60 locations in New Jersey. This collaboration aims to improve operational efficiency and patient experience, utilizing Phreesia's integrated platform within Epic’s system. Key achievements over the first 120 days include:

• 40,600 patients completed outcomes
• 54% registered before visits
• 84% copays paid at service
• 87% positive ratings of check-in

This integration is expected to support patient-focused care while minimizing in-person exposure.

Phreesia has partnered with the CONVINCE USA initiative at CUNY Graduate School of Public Health to develop a patient survey aimed at understanding COVID-19 vaccine hesitancy. Over 300,000 responses have been collected, highlighting disparities; 78% of those 65 and older are likely to vaccinate, versus less than half of essential workers. The survey equips providers with patient data to address concerns during visits. This initiative is part of Phreesia's Vaccine Management Solution, aiming to enhance vaccine access and education in vulnerable communities.

Phreesia, Inc. (NYSE: PHR) plans to release its fiscal fourth quarter and full year 2021 financial results on March 30, 2021, after market close. A conference call to discuss these results will be held on March 31, 2021, at 8:30 a.m. ET. Interested parties can join the call by dialing (866) 211-4557 or (647) 689-6750 for international calls, using conference code 3387628. Phreesia offers a robust SaaS platform to streamline patient intake processes, improving healthcare engagement and operational efficiency.

Phreesia has been awarded the 2021 Best in KLAS for Patient Intake Management by KLAS, an insights firm. The award recognizes top-performing healthcare IT companies based on feedback from healthcare organizations. Phreesia achieved a score of 91.3, reflecting provider evaluations across various customer experience areas. This marks the third consecutive year Phreesia has received top honors for this category, previously winning in 2020 and being named Category Leader in 2019. CEO Chaim Indig expressed gratitude to clients and team members for their support.

Phreesia, a leader in patient intake solutions, has received certification from the Alliance for Audited Media (AAM) for its PatientConnect platform. This certification validates that the platform’s advertising measurement systems adhere to high industry standards. Phreesia’s commitment to continuous auditing ensures accuracy and reliability, maintaining industry-level performance. AAM’s ongoing audits include evaluating targeting criteria and patient authorization processes. The collaboration emphasizes Phreesia’s transparency and data integrity in the healthcare advertising sector.